	US 11,938,098 B2
	Method for killing HIV-infected cells using Bcl-2 inhibitors
Andrew D. Badley, Rochester, MN (US); Amy M. Nguyen, Salt Lake City, UT (US); Scott H. Kaufmann, Rochester, MN (US); Yuan-Ping Pang, Rochester, MN (US); and Haiming Dai, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Mar. 16, 2021, as Appl. No. 17/203,594.
Application 17/203,594 is a continuation of application No. 15/567,855, abandoned, previously published as PCT/US2016/028419, filed on Apr. 20, 2016.
Claims priority of provisional application 62/149,873, filed on Apr. 20, 2015.
Prior Publication US 2021/0379086 A1, Dec. 9, 2021
Int. Cl. A61K 31/00 (2006.01); A61K 31/635 (2006.01); A61P 31/18 (2006.01); A61K 31/21 (2006.01); A61K 38/20 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/00 (2013.01) [A61K 31/635 (2013.01); A61P 31/18 (2018.01); A61K 31/21 (2013.01); A61K 38/2013 (2013.01); A61K 45/06 (2013.01)]

16 Claims

1. A method for increasing the susceptibility of HIV infected cells within a human to Casp8p41-mediated cell killing, wherein said method comprises administering a Bcl-2 inhibitor to said human, wherein said Bcl-2 inhibitor is ABT-199, ABT-263, or Sabutoclax, thereby increasing the susceptibility of HIV infected cells within said human to Casp8p41-mediated cell killing.